



BeyondSpring to Present at the 18th Annual Needham Healthcare Conference

April 4, 2019

NEW YORK, April 04, 2019 (GLOBE NEWSWIRE) -- [BeyondSpring Inc.](#) (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that management will provide a corporate overview at the 18th Annual Needham Healthcare Conference on Tuesday, April 9, 2019, at 8:00 a.m. Eastern Time at the Westin Grand Central Hotel in New York, NY.

The presentation will be webcast live and archived on BeyondSpring's website at www.beyondspringpharma.com under "[Events & Presentation](#)" in the Investors section.

About BeyondSpring

BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies. BeyondSpring's lead asset, Plinabulin, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and two Phase 2/3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has strong R&D capabilities with a robust pipeline in addition to Plinabulin, including three immuno-oncology assets and a drug discovery platform using the ubiquitination degradation pathway. The Company also has a seasoned management team with many years of experience bringing drugs to the global market.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements that are not historical facts. Words such as "will," "expect," "anticipate," "plan," "believe," "design," "may," "future," "estimate," "predict," "objective," "goal," or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company's future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet our expectations regarding the potential safety, the ultimate efficacy or clinical utility of our product candidates, increased competition in the market, and other risks described in BeyondSpring's most recent Form 20-F on file with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

Contact:

Media Relations:

Caitlin Kasunich / Kathryn Hunter

KCSA Strategic Communications

212.896.1241 / 212.896.1204

ckasunich@kcsa.com / khunter@kcsa.com

Investor Relations:

Stephen Kilmer

646.274.3580

stephen.kilmer@beyondspringpharma.com

BeyondSpring, Inc.